Category Archives: Biotechnology

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

NEW YORK, NY / ACCESSWIRE / October 15, 2021 / Sino United Worldwide Consolidated Ltd. (OTC PINK:SUIC) and Midas Touch Technology Ltd. have signed a strategic alliance partnership agreement with Taiwan Green Mountain Biotechnology Group to lead the countrywide marketing promotional activities and roadshows to kick off this quarter, aiming to establish 6,000 outlets in Taiwan and 30 other countries. SUIC, Midas are finalizing contracts with additional 5 partner distributors before the end of this year.

The partnership agreement was completed by the founder and Chairman of Green Mountain Biotechnology Group, Mr. Lin Jye and the CEO of Midas Touch, Mr. Joa Chen during a well-appointed signing ceremony hosted at the Taipei Regent Hotel on October 8, 2021 and attended by hundreds of merchants. The signing event had been widely covered by major media.

The Green Mountain Biotechnology Group is a leading beauty company in Taiwan specializing in manufacturing and marketing top quality skin care, makeup, fragrance and hair care products. The group Chairman, Mr. Lin Jye said, "This partnership with Midas Touch brings a positive energy that will benefit hundred thousands of business partners and generate tens of billions of dollars in business opportunities, while creating more than a million jobs in all parts of the world. Midas Touch has the mastery of operations and inventive approach that is unique and unparalleled in the market."

The Green Mountain Biotechnology group of companies has ten major business segments with a global scope covering more than 30 countries around the world. The holding group has captured the focus of major international media. It is one of the very few biotech companies in Taiwan that possesses cutting-edge technology research and development capabilities, global advanced production technology, and integrated brand marketing. The current product range covers medical and aesthetic skin care products, daily chemicals, nutritional supplements and smart living drinking water systems. Among the accolades it has gathered over the decades, its biotechnology company has received high recognition and won awards including the Taiwan Biotechnology Award, the Taiwan's No. 1 Brand Award, and the Taiwan Golden Quality Award, and the Global Quality Certification of Taiwan Ministry of Health. In addition to the Chinese market, the group's products are exported to more than 30 countries including the United States, Japan, South Korea, Malaysia, Singapore, the European Union, Thailand, Indonesia, Hong Kong, Macau, among others.

To learn more about Green Mountain Biotechnology group, please visit their website at:https://meihangjia.com/contact-us/

"SUIC-Midas is the first U.S. company that brings unique blockchain based solutions to Taiwan market for the digitization of real-world assets, unlocking their value in the process. We are very honored to have this opportunity to join the ranks of this pioneering "Supply Chain of Beauty" project and provide flexible funding strategies to businesses in the beauty industry and other industries in Taiwan and around the world. SUIC Midas not only offers one-of-a-kind solutions but also opportunities to grow businesses on a secure digital platform without losing the original characteristics of the physical assets. In January 2022, SUIC Midas will continue signing up more partners, while exclusive interviews with NASDAQ, Bloomberg, Fox Business and other major business news televisions have also been scheduled. This is a part of our global expansion plans to disrupt the traditional cash flow system and lead to the next generation of SUIC Midas supply chain finance ecosystem," explains Midas Touch media director, Henry Ho.

These five new partner distributors are expected to bring over 100,000 merchants which translates to $2 million royalty fees for the Midas Touch office in Taiwan. The New York and Malaysia offices will follow suit and launch the Starry Project before the end of the year, and will continue to launch in 40 countries in 2022/2023 replicating the Starry Project model and strategy.

About Midas Touch Technology Limited, United KingdomMidas Touch Technology Limited was established in the United Kingdom in 2010, is a duly registered company with a business license to operate. Midas Touch offers safeguards against fraud in the digital currency domain, e.g. counterfeit transfer of digital cash in wallets. Focus on digital asset management and provides enterprises with a decentralized finance (DeFi) and other comprehensive supply chain innovative financial services. Thereby, solve the capital turnover problems in both supply and demand sites. It has launched MT Flash Pay" Same Day Swipe-Funding, and MT CQ Pay" Emergency Loan with Double Revenues, MT Free Pay" Services - Delay Appropriation to Offset Transaction Cost and MT Unified Procurement" Combined Purchasing Powers Economies of Scale and several other financial solutions. To know more about Midas Touch, visit their website at http://www.midas-touch.io.

To learn more about Midas Touch product and services please review our information by clicking:https://drive.google.com/file/d/17GLXWv5T3d39Jrx2v0GvqKIBcSzxpOMy/view?usp=drivesdk

About Sino United Worldwide Consolidated Ltd., USAThe Sino United Worldwide Consolidated Ltd. provides research and development, venture financing for and investing in private enterprises and the public sector that develop products and services adopting core capabilities of the Internet of Things, cloud computing, mobile payment, Big Data, Blockchain, and Artificial Intelligence, to enhance and streamline existing processes, and establish new and exciting business models that will create revolutionary products and services. Shareholders of SUIC will be exposed to the diverse application of advanced services in various parts of the economy. Additionally, existing and potential customers can benefit from this company's diversified portfolio of technologies. As one of the pioneering publicly traded technology companies, SUIC will help build tech-enabled businesses of the future. To learn more, please visit http://www.sinounitedco.com.

Please also read the full company report on SUIC by Globe Small Cap Research LLC:https://drive.google.com/file/d/1_f2vaVOfJT5_idLn87lM1Q_lGxnY_tHW/view

Please also read the Updated Company PPT:https://drive.google.com/file/d/1jVOkxqxXFCRwrajwTQQ7xV7YIzn5wWF_/view?usp=sharing

Forward-Looking StatementCertain the information set forth herein contains "forward-looking information", including "future-oriented financial information"; and "financial outlook" under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of shares being offered hereunder; (iii) the expected development of the Company's business, projects, and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development, or otherwise under consideration; (vi) renewal of the Company's current agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained herein are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

ContactsSino United Worldwide Consolidated Ltd.New Release Department929-391-2550

SOURCE: Sino United Worldwide Consolidated Ltd.

View source version on accesswire.com: https://www.accesswire.com/668099/SUIC-Midas-Signed-Strategic-Partnership-Agreement-With-Taiwan-Biotech-Giant--Green-Mountain-Biotechnology-Group-To-Lead-The-Starry-Project-Countrywide-Roadshow-and-Global-Expansion-To-Open-6000-Outlets-in-30-Countries-SUIC-Midas-Is-Finalizing-The

The rest is here:
SUIC, Midas Signed Strategic Partnership Agreement With Taiwan Biotech Giant - Green Mountain Biotechnology Group To Lead The Starry Project...

Renowned industrialist and founder chairman of Praj Industries, Dr Pramod Chaudhari, who is popularly known as the Ethanol man, recently said that agricultural inputs form the base of biotechnology and these can be used to uplift the socio-economic status of farmers. Dr Chaudhari was speaking at an event held in his honour and hosted by United Western Business Forum at Hotel Sayaji in Wakad.

Dr Chaudhari was felicitated by Dr Anand Deshpande, the CMD of Persistent Systems, for being the first Indian recipient of the prestigious George Washington Carver Award, 2020.

Pune Mayor Murlidhar Mohol and PMRDA (Pune Metropolitan Region Development Authority) Commissioner Dr Suhas Diwase also attended the programme.

Dr Chaudhari said that biofuels are redefining transportation fuel mix and they also help combat climate change as they have low carbon content. The use of agricultural feedstock for production of biofuels provided an additional source of income to farmers, he added. Dr Chaudhari said that bio-based renewable chemicals and materials are the new frontier of bioeconomy.

Mohol said Dr Chaudharis achievement is a matter of pride for Puneites and added that People like Dr Chaudhari will inspire the youth of the city.

Dr Deshpande said an entrepreneur should always think about achieving the next level for his business, because any business can stagnate after reaching a certain level of success. He also suggested that a wide base of mentors was required to guide the entrepreneurs through difficult times.

The dean of alumni and corporate relations at IIT Bombay, Dr Suhas Joshi, said that the institute was in advanced stages of discussions with Dr Chaudhari for setting up a lifelong learning centre for IIT-B alumni. The institute has a strong base of over 65,000 alumni working across various segments and they have an urge to learn new skills from their alma mater, Joshi added.

Dr Diwase pointed out that biotechnology had the potential to make agriculture sustainable and economically viable. This will also help reduce urban influx and ease pressure on cities, he said. The current Covid-19 pandemic has shown the youth the importance of moving back to the fields rather than seeking opportunities in big cities, he said.

Read more from the original source:
Biotechnology can be used to improve condition of farmers, says Ethanol man - The Indian Express

PUNE, India, Oct. 15, 2021 /PRNewswire/ -- According to The Insight Partners study on "Contract Research Organization (CRO) Market to 2028 Global Analysis and Forecast by Type, End User, and Geography," the market is projected to reach US$ 88,835.19 million by 2028 from US$ 50,093.56 million in 2021; it is expected to grow at a CAGR of 8.5% during 20212028. The market growth is attributed to the surge in R&D expenditures and outsourcing activities, government initiatives to increase clinical trial participants, and rising number of clinical trials.

he Insight Partners Logo

North America would dominate the contract research organization (CRO) market in 2021. The market growth in the US is attributed to increasing research and development (R&D) expenditures. Various pharmaceutical companies are experiencing short profit margins due to patent expiry, which is compelling the spurring manufacturers to reduce their in-house R&D activities and outsource these activities to contract research organizations. Thus, the focus of biotechnology and pharmaceutical companies to lower the drug development costs propel the market in the US.

Get Exclusive Sample Pages of Contract Research Organization (CRO) Market at https://www.theinsightpartners.com/sample/TIPBT00002008/

Based on type, the contract research organization (CRO) market is segmented into early phase services, clinical research services, laboratory services, and post-approval services. The early phase services segment is further bifurcated into drug discovery services and preclinical services. The clinical research services segment is the largest shareholder in the market and is expected to register the highest CAGR during the forecast period. By end user, the contract research organization (CRO) market is segmented into pharmaceutical and biotechnology companies, and medical devices companies. The pharmaceutical and biotechnology companies segment holds a larger share of the market, and it is anticipated to register a higher CAGR in the market during the forecast period.

Story continues

Increasing R&D Expenditures and Outsourcing Activities Fuel Contract Research Organization (CRO) Market Growth

R&D is an essential and crucial part of any company's business. Pharmaceutical and biotechnology companies focus on the R&D to come up with new molecules or active ingredients with the greatest medical and commercial potential for various therapeutic applications. Companies invest majorly on R&D for delivering high-quality and innovative products to the markets they serve. Research and development expenditures entail spending on the discovering, testing, and developing new products; making upfront payments and milestones; improving existing products; and demonstrating product efficacy and regulatory compliance prior to launch. According to the International Federation of Pharmaceutical Manufacturers & Associations, in 2019, the R&D expenditures by the pharmaceuticals and biotechnology industry grew by ~20% than those in 2015.

With the second wave of COVID-19, there has been an increasing number of cases in Latin American countries. With the high focus on treating the disease, governments in this region are encouraging clinical programs to fight against the novel coronavirus. Moreover, the majority of manufacturing companies have channelized their efforts toward developing therapeutics against this disease. Thus, the pandemic has had a slightly negative effect on other healthcare markets, such as contract research organization market.

Download the Latest COVID-19 Analysis on Contract Research Organization (CRO) Market Growth Research Report at https://www.theinsightpartners.com/covid-analysis-sample/TIPBT00002008/

Contract Research Organization (CRO) Market: Segmental Overview

Based on end user, the pharmaceutical and biotechnology companies' segment is anticipated to register a higher CAGR in the contract research organization (CRO) market during the forecast period.

Contract Research Organization (CRO) Market: Competitive Landscape and Key Developments

IQVIA Inc; Parexel International Corporation; Charles River Laboratories, Inc.; ACM Global Laboratories; Merck KGaA (Bio Reliance Corporation); Celerion; Clinitude; Laboratory Corporation of America Holdings (Covance Inc.); Novotech; and Icon PLC are among the key companies operating in the contract research organization (CRO) market. Leading players focus on launch of new products, expansion and diversification of market presence, and acquisition of new customer base for tapping the prevailing business opportunities.

In June 2021, Charles River Laboratories completed the acquisition of Vigene Biosciences for US$ 292.5 million in cash. The acquisition of Vigene Biosciences' extensive gene therapy capabilities further enhances Charles River's position as a premier scientific partner for cell and gene therapies.

Order a Copy of Contract Research Organization (CRO) Market Shares, Strategies and Forecasts 2021-2028 Research Report at https://www.theinsightpartners.com/buy/TIPBT00002008/

In April 2021, IQVIA acquired Q2 Solutions, a clinical laboratory services organization of Quest Diagnostics.

In November 2020, WuXi Apptec expanded its Cell & Gene Therapy Platforms with capabilities to provide high-quality and cost-effective supplies of R&D and GMP plasmids.

Browse Related Reports:

About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi E-mail: sales@theinsightpartners.com Phone: +1-646-491-9876More Research: https://www.openpr.com/news/archive/139407/The-Insight-Partners.html

Cision

View original content:https://www.prnewswire.com/news-releases/contract-research-organization-cro-market-size-88-83-billion-by-2028-growth-forecast-at-8-5-cagr-during-2021-to-2028-covid-impact-and-global-analysis-by-the-insight-partners-301400770.html

SOURCE The Insight Partners

Originally posted here:
Contract Research Organization (CRO) Market Size ($88.83 Billion by 2028) Growth Forecast at 8.5% CAGR During 2021 to 2028 COVID Impact and Global...

FLORHAM PARK, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, will release financial results for the third quarter of 2021 on Wednesday, November 10, 2021, before the market opens. Following the release, management will host a conference call to review the companys financial results and provide a business update.

The conference call is scheduled to begin at 8:00 am ET on Wednesday, November 10, 2021. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company's website at http://www.pdsbiotech.com.

After the live webcast, the event will be archived on PDS Biotechs website for 6 months.

About PDS BiotechnologyPDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Companys proprietary Versamune T-cell activating technology platform. Our Versamune-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The companys pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck & Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA in a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer. PDS Biotech is also conducting two additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer with the National Cancer Institute (NCI) and The University of Texas MD Anderson Cancer Center, respectively.

Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely, believe, estimate, project, intend, forecast, guidance, outlook and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Companys ability to protect its intellectual property rights; the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the Companys dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Companys operations or require the Company to relinquish rights to the Companys technologies or product candidates; the Companys limited operating history in the Companys current line of business, which makes it difficult to evaluate the Companys prospects, the Companys business plan or the likelihood of the Companys successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune based products; the future success of such trials; the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune based products and the Companys or monitoring committees or other third parties interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the success, timing and cost of the Companys ongoing clinical trials and anticipated clinical trials for the Companys current product candidates, including statements regarding the timing of initiation, pace of enrollment, significance of milestones, and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Companys ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Companys product candidates, if approved; the timing of and the Companys ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Companys product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Companys control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Rich CockrellCG CapitalPhone: +1 (404) 736-3838Email: rich@cg.capital

Follow this link:
PDS Biotechnology : Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results - Marketscreener.com

The updated report on the Commercial Biotechnology Separation Systems market gives a precise analysis of the value chain assessment for the review period of 2021 to 2027. The research includes an exhaustive evaluation of the administration of the key market companies and their revenue-generating business strategies adopted by them to drive sustainable business. The Service industry report further enlists the market shortcomings, stability, growth drivers, restraining factors, opportunities for the projected timeframe.

Get Sample Report with Latest Industry Trends Analysis: https://www.a2zmarketresearch.com/sample-request/575979

The top companies in this report include: Danaher, Thermo Fisher Scientific, BD, Merck, GE Healthcare, Agilent, Sysmex, Alfa Wassermann, Shimadzu, Sartorius Stedim Biotech, Illumina, Waters, Novasep, 3M Purification, Affymetrix.

The Global Commercial Biotechnology Separation Systems market is expected to register a notable market expansion of XX% during the review period owing to the largest market value in 2019. The market study provides a measure of the effectiveness of the product, real-time Commercial Biotechnology Separation Systems market scenario, along custom ease. The study further offers market analysis, strategies and planning, R & D landscape, target audience management, market potential, due diligence, and competitive landscape.

Scope of the report:

A thorough analysis of statistics about the current as well as emerging trends offers clarity regarding the Commercial Biotechnology Separation Systems market dynamics. The report includes Porters Five Forces to analyze the prominence of various features such as the understanding of both the suppliers and customers, risks posed by various agents, the strength of competition, and promising emerging businesspersons to understand a valuable resource. Also, the report spans the Commercial Biotechnology Separation Systems research data of various companies, benefits, gross margin, strategic decisions of the worldwide market, and more through tables, charts, and infographics.

The Commercial Biotechnology Separation Systems report highlights an all-inclusive assessment of the revenue generated by the various segments across different regions for the forecast period, 2021 to 2027. To leverage business owners, gain a thorough understanding of the current momentum, the Commercial Biotechnology Separation Systems research taps hard to find data on aspects including but not limited to demand and supply, distribution channel, and technology upgrades. Principally, the determination of strict government policies and regulations and government initiatives building the growth of the Commercial Biotechnology Separation Systems market offers knowledge of what is in store for the business owners in the upcoming years.

Global Commercial Biotechnology Separation Systems Market Segmentation:

Market Segmentation: By Type

Membrane FiltrationLiquid ChromatographyCentrifugeElectrophoresisFlow CytometryOthers

Market Segmentation: By Application

PharmaceuticalFood & CosmeticsAgricultureOthers

Geographic analysis:

The global Commercial Biotechnology Separation Systems market has been spread across North America, Europe, Asia-Pacific, the Middle East and Africa, and the rest of the world.

Get Exclusive Discount on this Premium Report: https://www.a2zmarketresearch.com/discount/575979

COVID-19 Impact Analysis

The pandemic of COVID-19 has emerged in lockdown across regions, line limitations, and breakdown of transportation organizations. Furthermore, the financial vulnerability Commercial Biotechnology Separation Systems Market is a lot higher than past flare-ups like the extreme intense respiratory condition (SARS), avian influenza, pig influenza, bird influenza, and Ebola, inferable from the rising number of contaminated individuals and the vulnerability about the finish of the crisis. With the rapid rising cases, the worldwide Commercial Biotechnology Separation Systems refreshments market is getting influenced from multiple points of view.

The accessibility of the labor force is by all accounts disturbing the inventory network of the worldwide Commercial Biotechnology Separation Systems market as the lockdown and the spread of the infection are pushing individuals to remain inside. The presentation of the Commercial Biotechnology Separation Systems makers and the transportation of the products are associated. If the assembling movement is stopped, transportation and, likewise, the store network additionally stops. The stacking and dumping of the items, i.e., crude materials and results (fixings), which require a ton of labor, is likewise vigorously affected because of the pandemic. From the assembling plant entryway to the stockroom or from the distribution center to the end clients, i.e., application ventures, the whole Commercial Biotechnology Separation Systems inventory network is seriously compromised because of the episode.

The research provides answers to the following key questions:

Buy Exclusive Report: https://www.a2zmarketresearch.com/checkout

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

Read this article:
Commercial Biotechnology Separation Systems Market to Witness Robust Expansion by 2028 | Danaher, Thermo Fisher Scientific, BD, Merck, GE Healthcare ...

Apart from the special curriculum of Biotechnology & Bioinformatics, Computational Engineering & Industrial Chemistry, students will have an opportunity to increase their depth in the subject by undertaking elective courses from any other department & can also get a minor in areas of their interest, outside the department, like entrepreneurship, computer science, etc., by completing 12 additional credits in that area. In the 6th semester, students can opt for the semester-long projects which provide an opportunity to work & gain experience in Biotech/Pharma/Manufacturing/IT/Data Analysis/Chem Informatics & helps in the gradual transition to full-time jobs.

Adding the merits of BTech in Biotechnology & Bioinformatics, Prof Anindya Roy, said, The curriculum is designed to train the students with in-demand bioinformatics skills, including AI and soft computing, web technologies, structural biology, biological data mining, image processing, modelling and simulation, systems biology, and biostatistics to ensure the complete industry readiness of the students.

Citing the benefits of BTech in Computational Engineering, Prof Raja Banerjee, Department of Mechanical & Aerospace Engineering, said, Students of Computational Engineering will receive an interdisciplinary education where they gain expertise in state-of-the-art numerical methods and algorithms, modelling and simulations of engineering systems and processes, high-performance computing, process control, and optimization, data analytics, and machine learning.

We have designed a unique 4 years BTech Program with particular emphasis on producing the finest graduate students with adequate knowledge of applied chemistry and technology to work in various industries like pharma & drug design, polymer industry, petrochemical industries, environment, & energy, etc., added Prof Satyanarayana G, Head Department of Chemistry, IIT Hyderabad.

Visit the website for details: https://iith.ac.in/news/2021/10/15/New-Industry-oriented-BTechs/.

Read more:
IIT Hyderabad Announces 1st of Its Kind Industry-oriented B.Tech Programs in Biotechnology & Bioinformatics, Computational Engineering and...

Polaris Market Research has released the latest research report on the Biotechnology Market. The report is a comprehensive numerical analysis of the market and provides data to formulate strategies to improve the growth and success of the market. This Biotechnology market report provides a detailed assessment of the market highlighting different aspects such as drivers, trends, opportunities, restraints, and challenges.

This comprehensive Biotechnology market research report utilizes effective and advanced tools and techniques including SWOT analysis and Porters five forces analysis. Market reports help strengthen the organization and make better decisions to keep the business on track. This report is a compilation of comprehensive research into all aspects of the Biotechnology Market. With accurate data and highly authentic information, it has made a wonderful attempt to provide a true and transparent picture of current and future conditions in the Biotechnology market.

Get FREE sample copy of the report : https://www.polarismarketresearch.com/industry-analysis/biotechnology-market/request-for-sample

This Report Sample Includes:

COMPETITOR ANALYSIS:

The competition model in Biotechnology market provides detailed information by the competitors. Detailed information includes company profile, company finances, revenue generated, market potential, R&D investments, new market plans, regional presence, strengths and weaknesses of the company. company, product launch, product width and breadth, and application advantages.

Some well-established players in the Biotechnology market are

Agilent Technologies, BioGen Medical Instruments, Danaher, F. Hoffmann-La Roche, Abbott Laboratories Illumina, Merck, PerkinElmer, Qiagen and Thermo Fisher Scientific, Amgen, Bio-Rad Laboratories

MARKET SEGMENTATION :

The report has conducted extensive research on the market segments and sub-segments and made it clear which market segment will dominate the market during the forecast period. In order to help clients to make informed decisions about business investment plans and strategies in the Biotechnology market, report provides detailed information regarding regional market performance and competitor analysis.

Segmentation by type: Type 1, Type 2

Segmentation by application: application 1, application 2

(Details in Sample Report, Download sample copy at FREE of cost)

Key points of the geographic analysis:

Ask For Discount Before Purchasing This Business Report @ https://www.polarismarketresearch.com/industry-analysis/biotechnology-market/request-for-discount-pricing

The latest business intelligence report analyzes the market in terms of market reach and customer base in key geographic market regions. The Biotechnology market can be geographically divided into:

Key questions answered in this report

If You Have Any Query, Ask Our Experts @ https://www.polarismarketresearch.com/industry-analysis/biotechnology-market/speak-to-analyst

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us

Corporate Sales, USA

Polaris market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web:www.polarismarketresearch.com

Go here to read the rest:
Biotechnology Market 2021 Covering Impact of COVID-19 and SWOT Analysis by Global Top Companies UNLV The Rebel Yell - UNLV The Rebel Yell

PHILADELPHIA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (AnPac Bio, the Company or we) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its Philadelphia, PA Clinical Laboratory Improvement Amendments (CLIA) certified laboratory has received accreditation from the College of American Pathologists (CAP). The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the governments own inspection program. During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory results, inspectors examine the laboratorys records and quality control of the procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and records, and overall management.

Anpac Bio is proud to have received this accreditation, said Dr. Pandit, the CLIA Laboratory director and CEO of Anpac Bio in the United States. The College of American Pathologists (CAP) is the gold standard in medical laboratory accreditation. Through this rigorous inspection process, CAP has certified that Anpac Bio is meeting the highest standards in quality patient care. We have strived from the beginning to lead the industry in quality and innovation. CAP certification is a major milestone along our journey to deliver on our promise of ground-breaking science and commercialization for our novel cancer differentiation analysis (CDA) technology in the United States. We know that the CAP accreditation will only communicate further to our clients, research partners, and future patients, that Anpac Bio is committed to excellence and exceptional laboratory processes.

Dr. Chris Yu, CEO and Chairman of AnPac Bio commented: AnPac Bio is proud to join an outstanding group of select laboratories globally that have received this accreditation. With the CAP accreditation of our Philadelphia laboratory, we have now consolidated our California laboratory into one single expanded ultramodern facility in the USA. The CAP Accreditation for our Philadelphia facility demonstrates that our laboratory operates at the highest standards and is another key step in delivering on our mission to detect cancer early through the power of our CDA technology.

About the College of American Pathologists

As the worlds largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.

About AnPac Bio

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as ofMarch 31, 2021. With one CLIA- and CAP-registered clinical laboratory inthe United Statesand two certified clinical laboratories inChina, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomics tests. According to a Frost & Sullivans report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The Company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as ofMarch 31, 2021. AnPac Bios CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For more information, please visit: https://www.Anpacbio.com.

For investor and media inquiries, please contact:

Company:Phil Case, Marketing and Investor RelationsPhone: +1-267-810-6776 (US)Email:phil_case@AnPacbio.com

Investor Relations:Ascent Investor Relations LLCTina Xiao, PresidentPhone: +1-917-609-0333 (US)Email:tina.xiao@ascent-ir.com

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Companys future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including believes, estimates, anticipates, expects, plans, projects, intends, potential, target, aim, predict, outlook, seek, goal objective, assume, contemplate, continue, positioned, forecast, likely, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

See the rest here:
AnPac Bio's USA Laboratory Receives Accreditation from the - GlobeNewswire

The analyst presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions.

New York, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Drug Discovery and Early Development Outsourcing Growth Opportunities" - https://www.reportlinker.com/p06130908/?utm_source=GNW The report identifies the evolving competitive landscape and initiatives taken by key contract research organizations (CRO) and contract development and manufacturing organizations (CDMO) to adapt to the growing needs of pharmaceutical and biotechnology sponsors. The drug discovery and early development outsourcing market was worth $19.65 billion in 2020 and is estimated to grow at a compound annual growth rate of 6.4% up to 2026, with North America continuing to lead the market. In terms of overall R&D expenditure, the contribution of large pharmaceutical companies is steadily declining due to their focus on leaner portfolios. In contrast, the contribution of emerging biotechnology companies to drug development has grown more than 80% since 2018. Pharmaceutical companies are directing their R&D spending mainly toward strengthening their oncology portfolio and increasing year-on-year acquisitions of clinical-stage biopharmaceutical companies focusing on oncology therapy, suggesting both the potential of new technologies and promising returns on investment for these assets. Leading CROs and CDMOs are also focused on oncology, with anticancer drugs reportedly contributing the highest to the drug development pipeline in 2020. COVID-19-related drug discovery and early development research is projected to slow down in 2022 as most projects would have advanced to the clinical research stage by then. When pandemic-related restrictions are lifted, a surge in outsourcing for the next two years is expected as companies resume their non-COVID-19 drug discovery programs that were stalled during the pandemic.In the United States and Europe, testing service providers with best-in-class good laboratory practices (GLP) and good track records are the preferred partner for completing investigational new drugsenabling studies. Global CROs may have in-house capabilities, but pharmaceutical companies still prefer independent validation from specialists to minimize the risk of failure early on in the development life cycle before moving toward regulatory filing. Key industry participants are positioning themselves to be end-to-end integrated service providers for pharmaceutical and biotechnology sponsors. The growing demand for end-to-end integrated drug discovery and development support is closing the gap that distinguishes a CRO from a CDMO. The promise of artificial intelligence in drug discovery, along with novel approaches to target undruggable RNA, is set to drive small molecule drug discovery and outsourcing while the growth in biologics is expected to boost the need for better disease models and advanced in vivo pharmacology capabilities. Exploring novel expression systems to support the urgent needs of infectious disease management is also forecast to gain momentum especially as the industry favors single-use reactors for future biotherapeutics. Author: Meghna Hiren ThakkarRead the full report: https://www.reportlinker.com/p06130908/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Read the original post:
Global Drug Discovery and Early Development Outsourcing Growth Opportunities - Yahoo Finance

FARGO, N.D.--(BUSINESS WIRE)-- Agathos Biologics, a biotechnology company developing transformational science within a strong ethical and moral framework, today announced the company has been awarded $900,000 from the North Dakota Department of Agriculture Bioscience Innovation Grant (BIG) Program. Agriculture Commissioner Doug Goehring announced that nine grants have been awarded totaling $4.9 million to foster the growth of the bioscience industry in North Dakota. Advances in bioscience have already transformed many sectors including agriculture and medicine, Goehring said. These grants will help North Dakota stay on the forefront of bioscience innovation.

Agathos Biologics project funded by ND BIG will focus on challenges that limit patient access to advanced genetic medicines that can significantly impact quality of lifecost, availability, and ethical concerns. Company scientists will create new materials and methods for research and biomanufacturing and use them for drug development, which will address unmet medical needs and increase the availability of genetic medicines to more patients. The company will make these products and services available to the broader biotechnology industry through direct sales and licensing, partnerships, and collaborations.

We are honored to receive this support from the State of North Dakota and thank the Commissioner and the Committee for their work on behalf of the citizens of the state, said James Brown, Chief Executive Officer of Agathos Biologics. We founded the company in North Dakota because its business-friendly environment, skilled workforce, and growing biotechnology ecosystem make it an ideal place to expand the company and achieve our goal to develop genetic medicine products and services that positively impact human health and are ethically acceptable to all.

About Agathos Biologics

Agathos Biologics is a biotechnology company pursuing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy. Discoveries in bioprocessing and genetic characterization and control have created an abundance of scientific possibilities that can help us all lead better lives. Our mission as the good science company is to create breakthrough products and services within a strong ethical and moral framework that benefits everyone. We believe in science that serves and have a relentless focus on serving our clients, employees, and society. For more information, please visit http://www.agathos.bio.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005432/en/

Go here to see the original:
Agathos Biologics Receives $900,000 from the North Dakota Bioscience Innovation Grant Program - BioSpace